A PYMNTS Company

EU Regulators Soon Block Illumina, Grail Deal: Reports

By  |  July 27, 2022

EU antitrust regulators are expected to veto US life sciences firm Illumina’s acquisition of biotechnology company Grail, people familiar with the matter said on Wednesday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    There are doubts whether concessions offered by Illumina last week to address the European Commission’s concerns about the $8 billion cash-and-stock deal will boost competition, the people said.

    The concessions include royalty-free global licences for some of its patents and a three-year patent truce with Chinese rival BGI in Europe.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.